<DOC>
	<DOCNO>NCT01556763</DOCNO>
	<brief_summary>This study patient schizophrenia design provide preliminary evidence safety , tolerability , pharmacokinetics well effect cognitive function 2 dose EVP-6124 compare placebo give patient 's usual antipsychotic medication .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic Study EVP-6124 Patients With Schizophrenia</brief_title>
	<detailed_description>Study drug supply capsule orally administer daily total 21 day . Eligible subject admit inpatient study unit Day -6 ( six day first dose study drug administer ) remain confined inpatient study unit throughout dose phase . Safety assessment , PK sampling , cognitive testing perform .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Male female age 18 55 year ( inclusive ) . Females must surgically sterile , postmenopausal , use reliable contraception negative pregnancy test screen Day 1 . A clinical diagnosis schizophrenia schizoaffective disorder prescribe stable dose aripiprazole ( 10 30 mg/day ) , olanzapine ( 10 20 mg/day ) , paliperidone ( 3 12 mg/day ) , risperidone ( 2 16 mg/day ) minimum 2 week initial screen . In good general health expect complete clinical trial design . Body Mass Index ( BMI ) 18 kg/m^2 38 kg/m^2 ( inclusive ) screening . Adequate hearing , vision , language skill perform cognitive testing procedure specify protocol . Voluntarily provide informed consent sign informed consent form ( ICF ) indicate purpose study explain , willing able adhere study regimen study procedure describe ICF , include confinement requirement . Negative urine drug screen screen inpatient observation baseline period ( Day 6 ) , except shortacting benzodiazepine prescribe insomnia . Fluent English ( speak , write , read ) . Female subject pregnant breastfeeding . Any active clinically significant medical condition within 1 month ( 30 day ) prior screen . A history substance ( drug ) dependence substance alcohol abuse within 12 month randomization define Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) . A score &gt; 5 item PANSS ( Positive Negative Syndrome Scale ) Positive subscale baseline inpatient observation period ( Day 1 ) . Any laboratory test abnormality screen indicate hepatic renal dysfunction , laboratory test abnormality deem investigator clinically significant . Any hematologic malignancy solid tumor diagnose within 3 year prior study entry exception localize skin cancer carcinoma situ cervix . Known carrier HBsAg , HCV antibody , positive result HIV1 and/or HIV2 antibody . Uncooperative could complete study procedure . Received investigational drug within 30 day screen . Donated blood within 30 day randomization Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective</keyword>
	<keyword>CNS</keyword>
</DOC>